Top

Published in:

Open Access 01-12-2002 | Research article

Drug therapy and adverse drug reactions to terbutaline in obstetric patients: a prospective cohort study in hospitalized women

Authors: Dulce María Hernández-Hernández, María Josefa E Vargas-Rivera, Alejandro A Nava-Ocampo, José Antonio Palma-Aguirre, Héctor Sumano-López

Published in: BMC Pregnancy and Childbirth | Issue 1/2002

Abstract

Background

Adverse drug reactions (ADR's) could be expected more frequently in pregnant women. This study was performed in order to identify ADR's to tocolytic drugs in hospitalised pregnant women.

Methods

A prospective cohort study was performed in two General Hospitals of the Instituto Mexicano del Seguro Social (IMSS) in Mexico City. Two hundred and seven women undergoing labor, premature labor, threatened abortion or suffering any obstetric related disease were included. Drug prescription and signs and symptoms of any potential ADR were registered daily during the hospital stay. Any potential ADR to tocolytic drugs was evaluated and classified by three of the authors using the Kramer's algorithm.

Results

Of the 207 patients, an ADR was positively classified in 25 cases (12.1%, CI95% 8.1 to 17.5%). All ADR's were classified as minor reactions. Grouping patients with diagnosis of threatened abortion, premature labor or under labor (n= 114), 24 ADR's were related to terbutaline, accounting for a rate of 21.1 ADR's per 100 obstetric patients. Obstetric patients suffering an ADR were older than obstetric patients without any ADR. However, the former received less drugs/day × patient^-1 and had a shorter hospital stay (p < 0.05) whereas the dose of terbutaline was similar between the two groups. Terbutaline inhibited uterine motility in women with and without any ADR at a similar rate, 70 and 76% respectively (x² = 0.07; p = 0.8).

Conclusion

Terbutaline, used as a tocolytic drug, was related to a high frequency of minor ADRs and to a high rate of effcicacy.

Olsson S: The role of the WHO program on International Drug Monitoring in coordinating wolrdwide drug safety efforts. Drug Saf. 1998, 19: 1-10.CrossRefPubMed

Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998, 279: 1200-1205. 10.1001/jama.279.15.1200.CrossRefPubMed

Detournay B, Fagnani F, Ouyanne P, Haramburu F, Begaud B, Welsch M, Imbs JL: Cost of hospitalizations related to side-effects drugs (in French). Thérapie. 2000, 55: 137-139.PubMed

Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP: Adverse drug events in hospitalized patients. Excess lenght of stay, extra costs, aand attributable mortality. JAMA. 1997, 277: 301-306. 10.1001/jama.277.4.301.CrossRefPubMed

Walson PD: Therapeutic drug monitoring in special populations. Clin Chem. 1998, 44: 415-419.PubMed

Ghandour FZ, Knauss TC, Hricik DE: Immunosuppressive drugs in pregnancy. Adv Ren Replace Ther. 1998, 5: 31-37.PubMed

Becerril-Marténez MC, Díaz-Marténez A, Bondani-Guasti A: Introducción a la farmacovigilancia. México DF, Secretaría de Salud,. 1995, 13-14.

Instituto Nacional de Estadística, Geografía e Informática: XII Censo General de Población y Vivienda 2000: Síntesis de Resultados. IAEGI: Estados Unidos Mexicanos. [http://www.inegi.gob.mx]

Secretaría de Salud, Dirección General de Estadística e Informática del Sistema Nacional de Salud, Sistema Sectorial de Información en Salud: Principales servicios de hospitalización por institución de salud. Bol Inform Estad. 1997, 1: 25-43.

10.

Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, Newhouse JP, Weiler PC, Hiatt HH: Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Eng J Med. 1991, 324: 370-376.CrossRef

11.

Caranasos GJ, Stewart RB, Cluff LE: Drug-induced illness leading to hospitalization. JAMA. 1974, 228: 713-717. 10.1001/jama.228.6.713.CrossRefPubMed

12.

Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR: An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979, 242: 623-632. 10.1001/jama.242.7.623.CrossRefPubMed

13.

Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR: An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. JAMA. 1979, 242: 633-638. 10.1001/jama.242.7.633.CrossRefPubMed

14.

Leventhal JM, Hutchinson TA, Kramer MS, Feinstein AR: An algorithm for the operational assessment of adverse drug reactions. III. Results of tests among clinicians. JAMA. 1979, 242: 1991-1994. 10.1001/jama.242.18.1991.CrossRefPubMed

15.

Vargas-Rivera J, Hernández HDM, Sumano LH, Palma AA, Bondani GA, Ponce MH: Reacciones adversas a los medicamentos en pacientes pediátricos en dos hospitales de segundo nivel. Rev Med IMSS. 1996, 34: 421-427.

16.

Elwood MJ: Critical appraisal od epidemiological studies and clinical trials. New York, Oxford University Press. 1998, 104-108.

17.

Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics. 1977, 33: 159-174.CrossRefPubMed

18.

Capellá D, Laporte JR: Spontaneous notification of adverse drug reactions (in Spanish). In: Phncipios de epidemiología de los medicamentos. Edited by: Laporte JR, Tognoni G. 1993, Barcelona, Ediciones científicas y técnicas SA, 147-170.

19.

Venulet J, Bankowski Z: Harmonising adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences. Drug Saf. 1998, 19: 165-172.CrossRefPubMed

20.

Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR: Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 1997, 17: 374-389.CrossRefPubMed

21.

Mariani L, Minora T, Ventresca GP: Drug surveillance and adverse reactions to drugs. The literature and importance of historical data (in Italian). Clin Ter. 1996, 147: 653-672.PubMed

22.

Mariani L: Pharmacovigilance: education and continuing updating. The role of university institutes (in Italian). Clin Ter. 1998, 149: 219-225.PubMed

23.

Thurmann PA, Schmitt K: Detection and evaluation of adverse drug effects (in German). Med Klin. 2000, 95: 4-8.

24.

Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD: Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol. 1998, 46: 505-511. 10.1046/j.1365-2125.1998.00817.x.CrossRefPubMedPubMedCentral

25.

Ciorciaro C, Hartmann K, Kuhn M: Differences in the relative incidence of adverse drug reactions in relation to age? An evaluation of the spontaneous reporting system of SANZ (Swiss Drug Monitoring Center) (in German). Schweiz Med Wochenschr. 1998, 128: 254-258.PubMed

26.

Muñoz MJ, Ayani I, Rodriguez-Sasiain JM, Gutiérrez G, Aguirre C: Adverse drug reaction surveillance in pediatric and adult patients in an emergency room (in Spanish). Med Clin (Barc). 1998, 111: 92-98.

27.

Tran C, Knowles SR, Liu BA, Shear NH: Gender differences in adverse drug reactions. J Clin Pharmacol. 1998, 38: 1003-1009.CrossRefPubMed

28.

Classen DC, Pestotnik SL, Evans RS, Burke JP: Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991, 266: 2847-2851. 10.1001/jama.266.20.2847.CrossRefPubMed

29.

Uppal R, Jhaj R, Malhotra S: Adverse drug reactions among inpatients in a north Indian referral hospital. Natl Med J India. 2000, 13: 16-18.PubMed

30.

Lam F, Elliott J, Jones JS, Katz M, Knuppel RA, Morrison J, Newman R, Phelan J, Willcourt R: Clinical issues surrounding the use of terbutaline sulfate for preterm labor. Obstet Gynecol Surv. 1998, 53 (suppl): S85-S95. 10.1097/00006254-199811002-00001.CrossRefPubMed

31.

Perry KG, Morrison JC, Rust OA, Sullivan CA, Martin RW, Naef RW: Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Am J Obstet Gynecol. 1995, 173: 1273-1277. 10.1016/0002-9378(95)91369-6.CrossRefPubMed

32.

Gyetvai K, Hannah ME, Hodnett ED, Ohisson A: Tocolytics for preterm labor: a systematic review. Obstet Gynecol. 1999, 94: 869-877. 10.1016/S0029-7844(99)00329-4.PubMed

33.

Kulier R, Hofmeyr GJ: Tocolytics for suspected intrapartum fetal distress. Cochrane Database Syst Rev. 2000, 2: CD000035-PubMed

34.

Eisler G, Hjertberg R, Lagercrantz H: Randomised controlled trial of effect of terbutaline before elective caesarean section on postnatal respiration and glucose homeostasis. Arch Dis Child Fetal Neonatal Ed. 1999, 80: F88-F92.CrossRefPubMedPubMedCentral

35.

Katz Z, Lancet M, Yemini M, Mogilner BM, Feigl A, Ben-Hur H: Treatment of premature labor contractions with combined ritodrine and indomethacine. Int J Gynaecol Obstet. 1983, 21: 337-342. 10.1016/0020-7292(83)90026-7.CrossRefPubMed

36.

Morales WJ, Smith SG, Angel JL, O'Brien WF, Knuppel RA: Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study. Obstet Gynecol. 1989, 74: 567-572.PubMed

37.

Challis JR, Lye SJ, Gibb W, Whittle W, Patel F, Alfaidy N: Understanding preterm labor. Ann N Y Acad Sci. 2001, 943: 225-234.CrossRefPubMed

38.

Zakar T, Hertelendy F: Regulation of prostaglandins synthesis in the human uterus. J Matern Fetal Med. 2001, 10: 223-235.CrossRefPubMed

39.

Frohn WE, Simmons S, Carlan SJ: Prostaglandin E2 gel versus misoprostol for cervical ripening in patients with premature rupture of membranes after 34 weeks. Obstet Gynecol. 2002, 99: 206-210. 10.1016/S0029-7844(01)01677-5.PubMed

40.

Scott JE, Grigsby PL, Hirst JJ, Jenkin G: Inhibition of prostaglandin synthesis and its effect on uterine activity during established premature labor in sheep. J Soc Gynecol Investig. 2001, 8: 266-276. 10.1016/S1071-5576(01)00124-1.CrossRefPubMed

41.

Ostensen M, Ramsey-Goldman R: Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?. Drug Saf. 1998, 19: 389-410.CrossRefPubMed

42.

Weintraub Z, Solovechick M, Reichman B, Rotschild A, Waisman D, Davkin O, Lusky A, Bental Y: Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2001, 85: F13-F17. 10.1136/fn.85.1.F13.CrossRefPubMedPubMedCentral

43.

Cuzzolin L, Dal-Cere M, Fanos V: NSAID-induced nephrotoxicity from the fetus to the child. Drug. 2001, 24: 9-18.

44.

Benesova O, Tejkalova H, Kristofikova Z, Husek P, Nedvidkova J, Yamamotova A: Brain maldevelopment and neurobehavioural deviations in adult rats treated neonatally with indomethacin. Eur Neuropsychopharmacol. 2001, 11: 367-373. 10.1016/S0924-977X(01)00102-X.CrossRefPubMed

45.

Kramer MS, Goulet L, Lydon J, Seguin L, McNamara H, Dassa C, Platt RW, Chen MF, Gauthier H, Genest J, Kahn S, Libman M, Rozen R, Masse A, Miner L, Asselin G, Benjamin A, Klein J, Koren G: Socio-economic disparities in preterm birth: causal pathaways and mechanisms. Pediatr Perinatal Epidemiol. 2001, 15 (suppl 2): 104-123. 10.1046/j.1365-3016.2001.00012.x.CrossRef

46.

Scott-Wright AO, Wrona RM, Flanagan TM: Predictors of infant mortality among college-educated black and white women, Davidson County, Tennessee, 1990–1994. J Natl Med Assoc. 1998, 90: 477-483.PubMedPubMedCentral

47.

Zeitlin JA, Ancel PY, Saurel-Cubizolles MJ, Papiernik E: Are risk factors the same for small for gestational age versus other preterm births?. Am J Obstet Gynecol. 2001, 185: 208-215. 10.1067/mob.2001.114869.CrossRefPubMed

48.

Arnold GJ: Clinical recognition of adverse drug reactions: obstacles and opportunities for the nursing profession. J Nurs Care Qual. 1998, 13: 45-55.CrossRefPubMed

49.

Morrison-Griffiths S, Pirmohamed M, Walley T: Reporting of adverse drug reactions: practice in the UK. Nurs Times. 1998, 94: 52-54.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2393/2/3/prepub

Title: Drug therapy and adverse drug reactions to terbutaline in obstetric patients: a prospective cohort study in hospitalized women
Authors: Dulce María Hernández-Hernández
María Josefa E Vargas-Rivera
Alejandro A Nava-Ocampo
José Antonio Palma-Aguirre
Héctor Sumano-López
Publication date: 01-12-2002
Publisher: BioMed Central
Published in: BMC Pregnancy and Childbirth / Issue 1/2002
Electronic ISSN: 1471-2393
DOI: https://doi.org/10.1186/1471-2393-2-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Drug therapy and adverse drug reactions to terbutaline in obstetric patients: a prospective cohort study in hospitalized women

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2002

Discordance between physical symptoms versus perception of severity by women with nausea and vomiting in pregnancy (NVP)

Humoral immune response to an allogenic foetus in normal fertile women and recurrent aborters

A criterion audit of women's awareness of blood transfusion in pregnancy

Intrauterine pregnancy following low-dose gonadotropin ovulation induction and direct intraperitoneal insemination for severe cervical stenosis

Prenatal diagnosis of Neu-Laxova syndrome: a case report

Elevated serum immunoglobulin E to Cryptomeria japonica pollen in rats exposed to diesel exhaust during fetal and neonatal periods